UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
| ||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Alumis Inc. | Common Stock | 022307102 | 26,066,617 | 1,959,896 | SH | SOLE | 1,959,896 | 0 | 0 | ||
| Arcellx, Inc. | Common Stock | 03940C100 | 129,510,510 | 2,346,630 | SH | SOLE | 2,346,630 | 0 | 0 | ||
| ARS Pharmaceuticals, Inc. | Common Stock | 82835W108 | 34,149,805 | 4,012,903 | SH | SOLE | 4,012,903 | 0 | 0 | ||
| CRISPR Therapeutics AG | Common Shares | H17182108 | 56,653,844 | 1,048,951 | SH | SOLE | 1,048,951 | 0 | 0 | ||
| Design Therapeutics, Inc. | Common Stock | 25056L103 | 21,863,695 | 6,526,476 | SH | SOLE | 6,526,476 | 0 | 0 | ||
| enGene Holdings Inc. | Common Shares | 29286M105 | 4,715,000 | 500,000 | SH | SOLE | 500,000 | 0 | 0 | ||
| KALA Bio, Inc. | Common Stock | 483119202 | 3,145,556 | 443,661 | SH | SOLE | 443,661 | 0 | 0 | ||
| Mineralys Therapeutics Inc. | Common Stock | 603170101 | 23,596,817 | 2,016,822 | SH | SOLE | 2,016,822 | 0 | 0 | ||
| Nkarta, Inc. | Common Stock | 65487U108 | 19,699,998 | 3,333,333 | SH | SOLE | 3,333,333 | 0 | 0 | ||